CLYM — Climb Bio, Inc.
$10.19-3.32%
Last close: · regular session
After-hours $10.19 0.00% ·
Last 60 sessions
Opening the full analysis uses 1 of your 3 free tickers today.
Chart, dilution, float and news for CLYM in the TickerWise workspace.
Climb Bio, Inc., a biotechnology company, focuses on developing therapies for autoimmune-driven inflammatory diseases. It develops budoprutug, an anti-CD19 monoclonal antibody for various autoimmune diseases, including systemic lupus erythematosus and lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024. Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wilmington, Delaware.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
- Exchange: NASDAQ
- Employees: 17
- Website: https://eliemtx.com
Latest SEC filings for CLYM
Latest CLYM news
- Climb Bio Presents Initial PrisMN Phase 2 Data from Budoprutug in pMN at an Oral Session at ASN Kidney Week 2026 Read article
- Climb Bio: Others Proved APRIL Works, So The Bet Is On The 12-Week Dosing Interval Read article
- Climb Bio to Present New Data at American Society of Nephrology (ASN) Kidney Week 2026 for CLYM116 and Budoprutug Read article
Opening the full analysis uses 1 of your 3 free tickers today.
Educational tool only — not investment advice.